Josep-Maria Ribera, Mireia Morgades, Olga Garcia-Calduch, Maialen Sirvent, Buenaventura Buendia, Marta Cervera, Hugo Luzardo, Jesus-Maria Hernandez-Rivas, Marta Sitges, Irene Garcia-Cadenas, Pau Abrisqueta, Pau Montesinos, Mariana Bastos-Oreiro, Maria-Paz Queipo De Llano, Pilar Bravo, Anna Torrent, Pilar Herrera, Antoni Garcia-Guinon, Ferran Vall-Llovera, Josefina Serrano, Maria-Jose Terol, Juan-Miguel Bergua, Ana Garcia-Noblejas, Cristina Barrenetxea, Laura Llorente, Daniel Garcia-Belmonte, Eva Gimeno, Antonia Cladera, Santiago Mercadal, Juan-Manuel Sancho
High dose-intensive or infusional intermediate-dose immunochemotherapy is highly effective treatment for Burkitt lymphoma irrespective of human immunodeficiency virus (HIV) infection. However, toxicities of these regimens are relevant, especially in older adults and elderly patients. The prospective multicenter BURKIMAB14 trial included four to six blocks of immunochemotherapy according to stage (localized: 1 and 2 non-bulky; advanced: 2 bulky, 3, 4) and age, with dose reduction in patients >55 years old...
February 1, 2024: Haematologica